BACKGROUND: Few data exist on long-term morbidity, overall survival, and graft survival of pediatric renal transplantation. METHODS: The authors performed a long-term cohort study in all Dutch patients, born before 1979, with onset of end-stage renal disease (ESRD) between 1972 and 1992 at age 0 to 15 years. Data on graft survival and determinants of outcome were obtained by reviewing all medical charts. The health status was assessed by cross-sectional examination of surviving patients. RESULTS: Three hundred ninety-seven transplantations were performed in 231 of all 249 patients, of whom 25 died with a functioning graft. Cardiovascular disease was the most prominent cause of death. Graft survival estimates for all transplantations were 59.2%, 45.3%, 35.4%, and 30.3% at 5, 10, 15, and 20 years, respectively. In comparison with azathioprine, cyclosporine as the immunosuppressant was associated with increased graft survival in retransplantations but not in first transplantations. Cross-sectional examination was performed on 110 patients. In 44 patients, the most recent graft survival exceeded 15 years. Co-morbidity was found in 40% of all patients; motor, hearing, or visual disabilities were found in 19%. Bone disease, headaches, itching, and tremors were the most reported disabling problems. Cyclosporine use was associated with hypertension and a history of epilepsy. Compared with all age-matched Dutch inhabitants, the educational attainment was low, and unemployment and parental dependency were high. CONCLUSIONS: The authors' results emphasize the need for reducing cardiovascular disease and metabolic bone disease in pediatric ESRD, a policy toward less toxic antirejection therapy, a more strict treatment of hypertension, and more attention for schooling and social development toward independence.
BACKGROUND: Few data exist on long-term morbidity, overall survival, and graft survival of pediatric renal transplantation. METHODS: The authors performed a long-term cohort study in all Dutch patients, born before 1979, with onset of end-stage renal disease (ESRD) between 1972 and 1992 at age 0 to 15 years. Data on graft survival and determinants of outcome were obtained by reviewing all medical charts. The health status was assessed by cross-sectional examination of surviving patients. RESULTS: Three hundred ninety-seven transplantations were performed in 231 of all 249 patients, of whom 25 died with a functioning graft. Cardiovascular disease was the most prominent cause of death. Graft survival estimates for all transplantations were 59.2%, 45.3%, 35.4%, and 30.3% at 5, 10, 15, and 20 years, respectively. In comparison with azathioprine, cyclosporine as the immunosuppressant was associated with increased graft survival in retransplantations but not in first transplantations. Cross-sectional examination was performed on 110 patients. In 44 patients, the most recent graft survival exceeded 15 years. Co-morbidity was found in 40% of all patients; motor, hearing, or visual disabilities were found in 19%. Bone disease, headaches, itching, and tremors were the most reported disabling problems. Cyclosporine use was associated with hypertension and a history of epilepsy. Compared with all age-matched Dutch inhabitants, the educational attainment was low, and unemployment and parental dependency were high. CONCLUSIONS: The authors' results emphasize the need for reducing cardiovascular disease and metabolic bone disease in pediatric ESRD, a policy toward less toxic antirejection therapy, a more strict treatment of hypertension, and more attention for schooling and social development toward independence.
Authors: Katherine Wesseling-Perry; Eileen W Tsai; Robert B Ettenger; Harald Jüppner; Isidro B Salusky Journal: Nephrol Dial Transplant Date: 2011-03-25 Impact factor: 5.992
Authors: Amy O Staples; Larry A Greenbaum; Jodi M Smith; Debbie S Gipson; Guido Filler; Bradley A Warady; Karen Martz; Craig S Wong Journal: Clin J Am Soc Nephrol Date: 2010-09-02 Impact factor: 8.237
Authors: Michelle R Denburg; Madhura Pradhan; Justine Shults; Abigail Jones; Jo Ann Palmer; H Jorge Baluarte; Mary B Leonard Journal: Pediatr Nephrol Date: 2010-06-22 Impact factor: 3.714
Authors: B Winkelmann; J Thumfart; D Müller; M Giessing; A Wille; S Deger; D Schnorr; U Querfeld; S Loening; J Roigas Journal: Urologe A Date: 2006-01 Impact factor: 0.639
Authors: Marieke J H van Summeren; Jeroen M Hameleers; Leon J Schurgers; Arnold P G Hoeks; Cuno S P M Uiterwaal; Thilo Krüger; Cees Vermeer; Wietse Kuis; Marc R Lilien Journal: Pediatr Nephrol Date: 2008-06 Impact factor: 3.714